公司简称：凯莱英 证券代码：002821 上海荣正企业咨询服务（集团）股份有限公司 关于 凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划（草案）修订稿 之 独立财务顾问报告 2025 年 3 月 | 一、 释义··································································································3 | | --- | | 二、声明 ···································································································4 | | 三、基本假设 ·····························································································5 | | 四、本激励计划的主要内容····················································· ...

北京德恒律师事务所 关于 凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划（草案）的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 | 一、本次激励计划的主体资格 | 3 | | --- | --- | | 二、本次激励计划的合法合规性 | 5 | | 三、本次激励计划涉及的法定程序 | 16 | | 四、本次激励计划的信息披露 | 18 | | 五、本次激励计划对公司和全体股东利益的影响 | 18 | | 六、结论意见 18 | | 北京德恒律师事务所 关于凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划（草案）的法律意见 北京德恒律师事务所 关于 凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划（草案）的 法律意见 德恒 01F20250024-01 号 致：凯莱英医药集团（天津）股份有限公司 北京德恒律师事务所（以下简称"本所"）受凯莱英医药集团（天津）股份 有限公司（以下简称"公司"或"凯莱英"）的委托，担任凯莱英 202 ...

Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6821） 董事會會議日期 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年3月28日（星期五）舉行，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2024年12月31日止年度業績及其發佈，並考慮建議派發末期 股息（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年3月14日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及李家聰先生組成。 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The prospects for biomanufacturing are broad, contributing to industrial upgrades. Biomanufacturing, centered on industrial biotechnology, utilizes enzymes and microbial cells in the processing of target products, including bio-based materials, chemicals, and bioenergy. Synthetic biology plays a crucial role as a platform technology in biomanufacturing. The global synthetic biology market is expected to maintain rapid growth, reaching nearly $50 billion by 2028 [3][4][22]. - Technological breakthroughs combined with policy support are driving the synthetic biology industry forward. Factors such as reduced costs of gene synthesis and sequencing, along with advancements in efficient gene editing technologies, provide a solid technical foundation for the rapid development of synthetic biology. Governments worldwide are increasingly prioritizing the development of synthetic biology, with various supportive policies being introduced [4][28]. - Synthetic biology is reshaping industrial models, offering more efficient and environmentally friendly synthesis solutions. It addresses issues associated with traditional chemical synthesis and natural extraction methods, such as high costs, limited yields, and environmental pollution. With breakthroughs in gene editing, enzyme engineering, and metabolic engineering, synthetic biology not only reduces drug production costs but also enhances capacity, enabling large-scale industrial production [4][5]. Summary by Sections Industry Overview - Biomanufacturing is defined as the processing of target products using industrial biotechnology, involving enzymes and microbial cells. Synthetic biology is a key platform technology in this field, enabling the design and construction of biological systems for various applications [13][14]. Policy Support and Technological Breakthroughs - The development of synthetic biology is supported by various policies and technological advancements. Governments are investing in funding, technology, and talent development to foster innovation and industrialization in this field [28][29]. - Major countries are establishing synthetic biology research centers and networks, with the UK and the US leading in policy initiatives to promote synthetic biology [29][30]. Synthetic Biology's Impact on Industrial Models - Synthetic biology is transforming production methods, achieving tasks that traditional biotechnologies cannot, while providing more efficient and eco-friendly synthesis options. This shift is crucial for addressing environmental challenges and enhancing production efficiency [4][5]. Investment Recommendations - Companies to watch include Chuan Ning Biological, Kingfisher Biotech, Kylin Biotech, and Huaxi Biological, which are positioned to benefit from the growth in synthetic biology [5].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The bio-manufacturing sector has vast potential and is poised to drive a new wave of industrial revolution, leveraging industrial biotechnology to produce bio-based materials, chemicals, and bioenergy [3][4] - The global synthetic biology market is expected to maintain rapid growth, projected to approach $50 billion by 2028, with a compound annual growth rate (CAGR) of approximately 24% from 2023 to 2028 [22][24] - Technological breakthroughs and policy support are driving the synthetic biology industry forward, with significant advancements in gene synthesis, sequencing, and editing technologies [4][37] Summary by Sections Industry Overview - Bio-manufacturing utilizes industrial biotechnology, enzymes, and microbial cells, playing a crucial role in producing bio-based materials and chemicals [13] - Synthetic biology is a design-driven science that re-engineers biological systems for useful purposes, with applications across various sectors including healthcare, agriculture, and chemicals [13][22] Policy Support and Technological Breakthroughs - Governments worldwide are increasingly prioritizing synthetic biology, with strategic plans and funding initiatives to support its development [28][29] - The reduction in costs for gene synthesis and sequencing technologies has laid a solid foundation for the rapid advancement of synthetic biology [37] Synthetic Biology Reshaping Industry Models - Synthetic biology is transforming production models, offering more efficient and environmentally friendly synthesis solutions compared to traditional methods [4][22] - The industry is expected to significantly reduce carbon emissions, with estimates suggesting a reduction of 1 to 2.5 billion tons of CO2 annually by 2030 through industrial biotechnology [4] Related Companies - Companies to watch include Chuan Ning Bio, Kingfisher Biotech, and Kailai Ying, which are positioned to benefit from advancements in synthetic biology [5] Investment Recommendations - The report suggests focusing on companies like Chuan Ning Bio, Kingfisher Biotech, and others that are leveraging synthetic biology for growth [5]

证券代码：002821 证券简称：凯莱英 公告编号：2025-009 公司自律监管指引第 10 号—股份变动管理》等有关规定，现将增持计划情况公 告如下： 一、本次增持计划基本情况 凯莱英医药集团（天津）股份有限公司 关于部分董事、高级管理人员和核心技术及业务人员 增持公司 A 股股份实施完成的公告 公司董事、高级管理人员和增持股份的核心技术及业务人员保证 公告内容真实、准确和完整，不存在虚假记载、误导性陈述或重大遗 漏。 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）部分董事、 高级管理人员和其他核心技术及业务人员拟自 2024 年 9 月 12 日起 6 个月内增 持公司 A 股股份，增持金额不低于人民币 2,000 万元（含）。具体内容详见公司 于 2024 年 9 月 12 日、2024 年 12 月 12 日在指定信息披露媒体发布的《关于部 分董事、高级管理人员和核心技术及业务人员增持公司 A 股股份计划的公告》 （公告编号：2024-083）和《关于部分董事、高级管理人员和核心技 ...

截至本公告披露日，肖毅先生直接持有公司股票274,420股，占公司总股本 0.0761%，通过公司《2022年员工持股计划》间接持有20,000股，占公司总股本 的0.0055%。肖毅先生承诺，其直接持有的公司股份将严格遵守《上市公司股东 减持股份管理暂行办法》及《深圳证券交易所上市公司自律监管指引第18号—股 东及董事、监事、高级管理人员减持股份》等相关规定；通过公司《2022年员工 持股计划》间接持有的公司股份，也将遵守公司《2022年员工持股计划》及《2022 年员工持股计划管理办法》等有关规定进行相应处理。 肖毅先生在公司任职期间勤勉尽责、恪尽职守，搭建及整合了公司工艺科学 中心（CEPS）先进技术平台，积极推动高通量筛选平台建设和应用，推进光化学、 电化学等先进技术应用，助力公司CDMO业务开展的同时，进一步夯实了公司的技 术储备。在此，公司及董事会对肖毅先生为公司发展所作的贡献表示衷心的感谢！ 特此公告。 凯莱英医药集团（天津）股份有限公司董事会 证券代码：002821 证券简称：凯莱英 公告编号：2025-008 凯莱英医药集团（天津）股份有限公司 关于高级管理人员退休离任的公告 本公司及董事会 ...

呈交日期: 2025年3月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-007 凯莱英医药集团（天津）股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要提示： 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"或"凯莱英"） 本次注销存放于回购专用证券账户中的部分股份 7,122,703 股，注销金额约 5.79 亿元，占注销前 A 股股本（340,164,843 股）的 2.09%，占注销前总股本的 1.94%。 本次回购股份注销完成后，公司 A 股股本由 340,164,843 股变更为 333,042,140 股，总股本 367,718,103 股由变更为 360,595,400 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购 股份注销事宜于 2025 年 2 月 26 日办理完成。 一、公司股票回购及使用情况 公司于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024 年第二次 H 股类别股东大会，审议通过了《 ...

Core Viewpoint - The company has approved a share repurchase plan, aiming to enhance shareholder value and investor confidence while maintaining operational stability and compliance with regulations [1][6]. Group 1: Share Repurchase Plan - The company will repurchase A-shares through centralized bidding in the secondary market, with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, at a maximum price of RMB 157 per share [1]. - The repurchase price cap was adjusted to RMB 155.27 per share effective from June 28, 2024, due to dividend distributions and other corporate actions [2]. - As of the announcement date, the company has completed the repurchase of 12,300,701 shares, accounting for 3.6161% of the total A-share capital, with a total expenditure of approximately RMB 999.64 million [4]. Group 2: Implementation Details - The repurchase was conducted from March 7, 2024, to February 18, 2025, with the highest transaction price at RMB 102.00 and the lowest at RMB 71.65 per share [4]. - The company has adhered to the relevant regulations during the repurchase process, ensuring compliance with the Shenzhen Stock Exchange's guidelines [9][10]. Group 3: Impact and Future Plans - The share repurchase is expected to establish a long-term incentive mechanism, protect shareholder rights, and enhance investor confidence without significantly impacting the company's operations or financial health [6]. - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period, with plans for future use in equity incentives or capital reduction [11].